Curis Lifesciences (NSE:CURIS) ROCE %: 27.06% (As of Mar. 2026)


NSE:CURIS Curis Lifesciences Ltd NSE:CURIS
19 GF Score
Price ₹99.40
! 2 Warning Signs
View Full Analysis

What is Curis Lifesciences ROCE %?

Curis Lifesciences NSE:CURIS 19 ROCE % is 27.06% as of Mar. 2026. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Curis Lifesciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 27.06%.

Curis Lifesciences  (NSE:CURIS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Curis Lifesciences ROCE % Related Terms

Curis Lifesciences ROCE % Historical Data

* Premium members only.

The historical data trend for Curis Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curis Lifesciences ROCE % Chart

Curis Lifesciences Annual Data
Trend Mar23 Mar24 Mar25 Mar26
ROCE %
31.45 59.73 49.69 27.06

Curis Lifesciences Semi-Annual Data
Mar23 Mar24 Mar25 Mar26
ROCE % 31.45 59.73 49.69 27.06
NSE:CURIS
19GF Score
Curis Lifesciences Ltd NSE:CURIS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Curis Lifesciences ROCE % Calculation

Curis Lifesciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=107.001/( ( (425.347 - 175.771) + (815.207 - 274.034) )/ 2 )
=107.001/( (249.576+541.173)/ 2 )
=107.001/395.3745
=27.06 %

Curis Lifesciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Mar. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Mar. 2025 )(Q: Mar. 2026 )
=107.001/( ( (425.347 - 175.771) + (815.207 - 274.034) )/ 2 )
=107.001/( ( 249.576 + 541.173 )/ 2 )
=107.001/395.3745
=27.06 %

(1) Note: The EBIT data used here is one times the annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.06% mean?
Curis Lifesciences (NSE:CURIS) has a ROCE % of 27.06% as of Mar. 2026.
Is Curis Lifesciences' ROCE % too high?
Curis Lifesciences' current ROCE % is 27.06%. The Drug Manufacturers industry median ROCE % is 7.03. Curis Lifesciences' value of 27.06% is 284.9% above this industry median. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' ROCE % compare to ZTS and UTHR?
Curis Lifesciences' ROCE % of 27.06% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Curis Lifesciences' value of 27.06% is 284.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current ROCE % of 27.06% is 284.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current ROCE % is 27.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current ROCE % of 27.06%. The current ROCE % is 27.06% and 284.9% above the Drug Manufacturers industry median of 7.03. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current ROCE % is 27.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curis Lifesciences Business Description

Address PF-23, GIDC Sanand - II, Industrial Acme Pharma, Opposite Teva Pharma, Sanand, Ahmedabad, GJ, IND, 382110
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score

Get the complete analysis for NSE:CURIS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹99.40
Price